Fatality due to intravenous diltiazem for acute ventricular rate control

Lynette R. Moser, Edward A Panacek, Mark A. Munger

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Progressive, sustained bradycardia resulting in asystole and subsequent death is reported in a 70-year-old woman with hyperkalemia and suspected digoxin toxicity following a 0.25 mg/kg intravenous diltiazem dose for treatment of atrial fibrillation with a rapid ventricular response. The possible pharmacodynamic and pharmacokinetic interactions between diltiazem, digoxin, and an elevated plasma potassium concentration are discussed and related to the outcome of the case. The routine practice of concomitant administration of diltiazem for rapid ventricular rate control and digoxin for long-term control may be dangerous in a subset of patients.

Original languageEnglish (US)
Pages (from-to)306-310
Number of pages5
JournalPharmacotherapy
Volume16
Issue number2 I
StatePublished - 1996

Fingerprint

Diltiazem
Digoxin
Hyperkalemia
Bradycardia
Heart Arrest
Atrial Fibrillation
Potassium
Pharmacokinetics
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Fatality due to intravenous diltiazem for acute ventricular rate control. / Moser, Lynette R.; Panacek, Edward A; Munger, Mark A.

In: Pharmacotherapy, Vol. 16, No. 2 I, 1996, p. 306-310.

Research output: Contribution to journalArticle

Moser, Lynette R. ; Panacek, Edward A ; Munger, Mark A. / Fatality due to intravenous diltiazem for acute ventricular rate control. In: Pharmacotherapy. 1996 ; Vol. 16, No. 2 I. pp. 306-310.
@article{011242f8b13548ab8bf8ea27634700ea,
title = "Fatality due to intravenous diltiazem for acute ventricular rate control",
abstract = "Progressive, sustained bradycardia resulting in asystole and subsequent death is reported in a 70-year-old woman with hyperkalemia and suspected digoxin toxicity following a 0.25 mg/kg intravenous diltiazem dose for treatment of atrial fibrillation with a rapid ventricular response. The possible pharmacodynamic and pharmacokinetic interactions between diltiazem, digoxin, and an elevated plasma potassium concentration are discussed and related to the outcome of the case. The routine practice of concomitant administration of diltiazem for rapid ventricular rate control and digoxin for long-term control may be dangerous in a subset of patients.",
author = "Moser, {Lynette R.} and Panacek, {Edward A} and Munger, {Mark A.}",
year = "1996",
language = "English (US)",
volume = "16",
pages = "306--310",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "2 I",

}

TY - JOUR

T1 - Fatality due to intravenous diltiazem for acute ventricular rate control

AU - Moser, Lynette R.

AU - Panacek, Edward A

AU - Munger, Mark A.

PY - 1996

Y1 - 1996

N2 - Progressive, sustained bradycardia resulting in asystole and subsequent death is reported in a 70-year-old woman with hyperkalemia and suspected digoxin toxicity following a 0.25 mg/kg intravenous diltiazem dose for treatment of atrial fibrillation with a rapid ventricular response. The possible pharmacodynamic and pharmacokinetic interactions between diltiazem, digoxin, and an elevated plasma potassium concentration are discussed and related to the outcome of the case. The routine practice of concomitant administration of diltiazem for rapid ventricular rate control and digoxin for long-term control may be dangerous in a subset of patients.

AB - Progressive, sustained bradycardia resulting in asystole and subsequent death is reported in a 70-year-old woman with hyperkalemia and suspected digoxin toxicity following a 0.25 mg/kg intravenous diltiazem dose for treatment of atrial fibrillation with a rapid ventricular response. The possible pharmacodynamic and pharmacokinetic interactions between diltiazem, digoxin, and an elevated plasma potassium concentration are discussed and related to the outcome of the case. The routine practice of concomitant administration of diltiazem for rapid ventricular rate control and digoxin for long-term control may be dangerous in a subset of patients.

UR - http://www.scopus.com/inward/record.url?scp=0029869106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029869106&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 306

EP - 310

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 2 I

ER -